Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial

Journal article

Key PointsQuestion  In men aged 50 to 69 years, does a single invitation for a prostate-specific antigen (PSA) screening test reduce prostate cancer mortality at 15-year follow-up compared with no invitation for testing?Findings  In this secondary analysis of a randomized clinical trial of 415 357 men aged 50 to 69 years randomized to a single invitation for PSA screening (n = 195 912) or a control group without PSA screening (n = 219 445) and followed up for a median of 15 years, risk of dea...

Expand abstract

Authors: Keeney, E; Sanghera, S; Martin, RM; Gulati, R; Wiklund, F

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Springer
• Journal: PharmacoEconomics
• Volume: 40
• Issue: 12
• Pages: 1207-1220
• Publication date: 2022-10-06
• DOI: 10.1007/s40273-022-01191-1
• EISSN: 1179-2027
• ISSN: 1170-7690
• Language: English
• Keywords: Cancer; Internal medicine; Decision analysis; Health economics; Pharmacoeconomics; Cost effectiveness; Nursing; Mathematics; Risk analysis (engineering); Prostate cancer; Medicine; Public health; Quality of Life Research; Cost-effectiveness analysis; Health administration; Oncology; Statistics; Intensive care medicine; Quality-adjusted life year